-
公开(公告)号：US20200277393A1
公开(公告)日：2020-09-03
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09683046B2
公开(公告)日：2017-06-20
申请号：US14790144
申请日：2015-07-02
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US10689453B2
公开(公告)日：2020-06-23
申请号：US16382645
申请日：2019-04-12
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
4.发明授权公开(公告)号：US10301392B2
公开(公告)日：2019-05-28
申请号：US15596609
申请日：2017-05-16
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US20170066831A1
公开(公告)日：2017-03-09
申请号：US14939624
申请日：2015-11-12
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
Patent Agency Ranking
公开(公告)号：US09090694B2
公开(公告)日：2015-07-28
申请号：US13798204
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US11732050B2
公开(公告)日：2023-08-22
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09951137B2
公开(公告)日：2018-04-24
申请号：US14939624
申请日：2015-11-12
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
-
公开(公告)号：US20170320957A1
公开(公告)日：2017-11-09
申请号：US15596609
申请日：2017-05-16
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
公开(公告)号：US09102737B2
公开(公告)日：2015-08-11
申请号：US13835518
申请日：2013-03-15
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.021 seconds)
